Latest Conference Articles

September 17th 2021, 2:36pm

ESMO Congress

Similarities in clinical characteristics in these patients despite differences in other genomic alterations may impact potential clinical trial treatment selection.

September 17th 2021, 2:20pm

ESMO Congress

Patients with renal cell carcinoma and their families may have a lack of understanding about the disease, clinical trials, and psychosocial impact.

September 16th 2021, 10:18pm

Frontline immunotherapy resulted in improved progression-free survival and overall survival compared with sunitinib in patients with advanced renal cell carcinoma; however, determining the benefit in those with favorable-risk disease must be examined further.

September 16th 2021, 9:50pm

ESMO Congress

Brigatinib resulted in a 52% reduction in the risk of disease progression or death and a 56% reduction in the risk of intracranial progression compared with crizotinib in patients with ALK-positive non–small cell lung cancer, according to final data from the phase 3 ALTA-1L trial.

September 16th 2021, 9:43pm

ESMO Congress

Mobocertinib displayed a manageable safety profile across 40-mg, 120-mg, and 160-mg dose cohorts in Japanese patients with non–small cell lung cancer, which, when coupled with pharmacokinetic analysis, led to the determination of 160 mg as the maximum tolerated dose and recommended phase 2 dose for further study in this population.

September 16th 2021, 9:10pm

ESMO Congress

Mobocertinib, a novel EGFR tyrosine kinase inhibitor, exhibited clinically meaningful activity in patients with non–small cell lung cancer who harbor EGFR exon 20 insertion mutations following frontline platinum-based chemotherapy when compared indirectly with real-world data of patients treated with standard of care.

September 16th 2021, 6:35pm

ESMO Congress

Linagliptin plus atezolizumab was linked with limited responses as a second-line treatment for patients with locally advanced or metastatic gastric or gastroesophageal junction cancer who participated in an arm of the open-label, phase 1b/2 MORPHEUS platform.

September 16th 2021, 5:35pm

ESMO Congress

Patients with endometrial cancer who had a high tumor mutational burden experienced high responses to single-agent dostarlimab-gxly, irrespective of mismatch repair or microsatellite stability status.

September 16th 2021, 4:28pm

Patients with clear cell renal cell carcinoma who received the combination of pembrolizumab and axitinib over sunitinib showed a benefit in adjusted overall survival and type and timing of subsequent therapy in a second interim analysis of the phase 3 KEYNOTE-426 study.

September 16th 2021, 4:09pm

ESMO Congress

The safety profile of daralutamide in combination with androgen-deprivation therapy was similar to placebo in patients with nonmetastatic castration-resistant prostate cancer.

September 16th 2021, 3:28pm

ESMO Congress

Treatment with darolutamide was associated with statistically significant benefits in episodic memory by computerized cognitive assessment compared with enzalutamide in patients with metastatic castration-resistant prostate cancer.

September 16th 2021, 1:18pm

ESMO Congress

The 2021 ESMO Congress, held as a virtual format for the second consecutive year, is fast approaching and isn’t holding back in terms of pivotal data across malignancies, especially in breast cancer and gynecologic cancers.

September 15th 2021, 5:00pm

American Urological Association Annual Meeting

By studying olaparib-sensitive and -resistant cell lines, researchers were able to gather insights regarding PARP inhibitor treatment and resistance mechanisms, including the use of CDK inhibition as a potential means of overcoming PARP inhibitor resistance in prostate cancer.

September 14th 2021, 8:50pm

American Urological Association Annual Meeting

Olaparib was still found to produce greater clinical benefit than enzalutamide or abiraterone acetate in patients with metastatic castration-resistant prostate cancer when the novel hormonal agents were examined separately rather than combined.

September 14th 2021, 6:44pm

IASLC World Conference on Lung Cancer

The clinical response to sotorasib could vary in patients with KRAS G12C–mutated non–small cell lung cancer depending on their co-mutational status.

September 14th 2021, 12:24pm

American Urological Association Annual Meeting

Large surface area microparticle docetaxel administered via direct intramural injection and intravesical instillations was found to be safe and showed preliminary signs of efficacy in patients with high-risk non-muscle invasive bladder cancer.

September 13th 2021, 9:07pm

American Urological Association Annual Meeting

Toni K. Choueiri, MD, discusses the results of the KEYNOTE-564 study in renal cell carcinoma.

September 13th 2021, 9:00pm

American Urological Association Annual Meeting

Karim Chamie, MD, discusses the design of the phase 2/3 QUILT-3.032 trial in patients with Bacillus Calmette-Guerín–unresponsive, non–muscle invasive bladder cancer carcinoma in situ.

September 13th 2021, 8:36pm

American Urological Association Annual Meeting

Neal D. Shore, MD, FACS, discusses the results of the randomized, open label, phase 2 ENACT trial in prostate cancer.

September 13th 2021, 8:05pm

American Urological Association Annual Meeting

Treatment with the mitomycin-containing reverse thermal gel UGN-101 resulted in a lengthy period of durable response when administered as induction treatment in patients with low-grade upper tract urothelial carcinoma.